이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

AQUALIS:프랑스에서 아칼라브루티닙으로 치료받은 CLL 환자의 삶의 질, PLATON 데이터베이스의 데이터를 기반으로 한 후향적 연구 (AQUALIS)

2026년 10월 23일 업데이트: AstraZeneca

AQUALIS: 프랑스에서 아칼라브루티닙으로 치료받은 만성 림프구성 백혈병 환자의 삶의 질: PLATON 데이터베이스에서 추출한 데이터를 기반으로 한 후향적 관찰 연구

QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting.

The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and twelve months after, in a real-life setting.

연구 개요

상태

모병

상세 설명

PROTOCOL SYNOPSIS

Background/Rationale:

CLL is the most prevalent leukemia among adults. The estimated incidence of CLL was 4 674 in 2018 in France, 59% in men with a median age of 71 in men and 73 in women. 95% of patients are older than 51 yrs at diagnosis. 5-yr survival is above 89% for patients diagnosed between 2010 and 2015. Yet, CLL cannot be cured. Some patients will require monitoring while others need to be treated. Treatment is based on both chemo-immunotherapies (CIT) and target therapies. Treatment choice depends on several parameters: age, patient general condition, comorbidities, prognostic factors, cytogenetic status. CIT have shown to improve overall survival (OS). Targeted therapies have changed the management and offer treatment options among older patients and those with comorbidities who have unacceptable side effects with CIT. Acalabrutinib (also known as ACP-196 and Calquence®), is a selective and irreversible small molecule inhibitor of BTK. Authorized as 1st or 2nd line treatment in France in November 2020. Its safety and efficacy were explored in phase III clinical trials ELEVATE-TN, ASCEND, and ELEVATE-R/R. Because CLL is, by definition, a chronic disease and requires long-term treatment and because many patients have comorbidities, it is essential to consider quality of life (QoL) of patients.14 In addition, the condition itself substantially impacts QoL.Patients with CLL experienced worse QoL than the general population across several domains, including symptoms (e.g. fatigue and sleep disturbances), as well as physical and mental functioning. Acalabrutinib has shown great efficacy associated with a good safety profile in clinical trials11,12,14. Moreover, it is an oral treatment that does not require intravenous injections when taken as monotherapy. This treatment modality associated with the favorable safety profile of acalabrutinib could have a positive impact on the QoL of patients. Indeed, patients could continue to live a normal life at home, surrounded by their relatives. QoL is often not assessed in real-world (RW) studies; hence, there is limited understanding about the RW QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting. The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and 12 months after, in a real-life setting.

Objectives:

Primary Objective : To measure QoL score of CLL patients treated with acalabrutinib, from treatment initiation and up to 12 months -Overall scores and scores in each domain of QoL questionnaires (EORTC-QLQ-C30 ) at acalabrutinib treatment initiation and at 3, 6, 9 and 12 months after initiation -Proportion of patients with an increase, a decrease, or no change in QoL scores over time (between each time point) Main Secondary Objectives: To describe QoL and precisely the level and evolution of all symptoms -Patients demographics (age, gender…) at acalabrutinib treatment initiation -Clinical characteristics at acalabrutinib treatment initiation (CLL diagnosis, Binet classification, comorbidities of interest) -Clinical characteristics quarterly up to 12 months (disease status) -Score is calculated with standardized EORTC-CLL17 questionnaire At acalabrutinib treatment initiation and at 3, 6, 9 and 12 months after initiation To measure the evolution of observance -Score is calculated with standardized GIRERD grid at 3, 6, 9 and 12 months after initiation To describe treatment patterns in CLL patients treated with acalabrutinib, overall and by age group -Acalabrutinib treatment: line, monotherapy or with obinutuzumab, posology, duration, reason for discontinuation if any To describe participating sites characteristics -Type of physician practice (public/private/mixed) -Type of care structure (CHU/ CHG…) -Existing patient support program (yes/no, type) Methods: Study design: This is a retrospective, observational study focusing on the QoL and experience of CLL patients treated with acalabrutinib in France in a real-life setting. This study is using secondary data of patients included in the national multicenter longitudinal cohort PLATON (sponsor HOSPITALIDEE) (clinical trial registration N° 2023-A01569-36). This cohort is enrolling patients with hematological malignancies including CLL patients. A follow-up of 12 months from initial cancer diagnosis / or patient enrollment is planned in the PLATON study. The current AQUALIS study mainly aims at describing CLL patient QoL and experience from acalabrutinib initiation, quarterly and up to 12 months post initiation. Patient and disease characteristics, treatment patterns, disease status over time will also be described. Thus, the patient population eligible for entering the AQUALIS study will be treatment naïve CLL patients enrolled in the PLATON study and having initiated acalabrutinib, at the time of data extraction. Only patients with a full T0 will be considered as included. Several data extraction from PLATON database and data cut-off are planned to address AQUALIS study objectives and planned publication plan. No extra-visit, nor specific additional examination nor intervention are required for patients eligible to enter the AQUALIS study. Data to be extracted and analyzed will be exclusively those already recorded in the PLATON database. HOSPITALIDEE will insure that in each center participating to PLATON cohort, all patients fulfilling the PLATON eligibility criteria have been informed about the PLATON study before being enrolled in the PLATON database and do not object to secondary use of their data. The AQUALIS study does not involve human person according to the French legislation. Data Source(s): The AQUALIS study will be a secondary use of data issued from the French PLATON cohort. The PLATON cohort is a national prospective cohort enrolling patients diagnosed with malignant hemopathies, aiming at to offer personalized information to patients to improve their QoL and guide their use of complementary care. PLATON is designed to ensure patients follow-up in the long term and on a European scale. This project is sponsored by HOSPITALIDEE and coordinated by Loic Raynal under the scientific responsibility of Pr Loïc Ysebaert. The sponsor has been granted with appropriate regulatory and ethics local approvals for the conduct of the study. Patients eligible to PLATON are informed about the study and are requested to sign a specific informed consent if they do agree for participation and for their data being processed. It is planned that 120 patients are enrolled and followed-up to 12 months from enrollment. Data are collected at patient inclusion, and on a regular basis (every 3 months) during the follow-up, according to routine practice. Socio-demographic, clinical, biological data, treatments patterns, etc..(Pathology, treatments, history, lifestyle, sociodemographic analysis, patient profile, preferences…) are collected via an electronic data capture tool and hosted in a centralized securized data center. Patient QoL and experience is also collected at 5 timepoints using 4 questionnaires . The PLATON database is managed by HOSPITALIDEE using their own software. A data-management plan and a consistency check program were established during database development. Quality controls of the data are performed: i) automatic data consistency check; ii) data management control through regular sending of queries; iii) regular e-control of entered data by the project manager; iv) remote and / or on-site data monitoring of at least 100% of the data entered. Data collection and hosting, data management, and statistical analysis of PLATON data are handled by HOSPITALIDEE. No patient-level data will be transmitted to AstraZeneca. Only aggregated data will be delivered, based on the current AQUALIS protocol and a related statistical analysis plan. Study population The AQUALIS study population will be a subgroup of patients enrolled in PLATON database following inclusion and exclusion criteria as described below.

Inclusion-Exclusion criteria: please see details in "ELIGIBILITY" SECTION. Outcome(s): Please see details "OUTCOME MEASURES" SECTION.

Patient study questionnaires :

In our research protocol, we have chosen the EORTC QLQ-C30 as our primary tool for evaluating quality of life. To address the potential overlap with the MD Anderson Symptom Inventory (MDASI), we have substituted the MDASI with the QLQ-CLL17, a supplementary module to the QLQ-C30 specifically designed for chronic lymphocytic leukemia. This addition enhances the relevance and specificity of our study's context. Alongside the QLQ-C30, the QLQ-CLL17 provides a comprehensive assessment tailored to our research objectives. Furthermore, we have opted to use neither FACIT-TS-G questionnaire nor the Cancer Therapy Satisfaction Questionnaire (CTSQ). Our decision was influenced by concerns about redundancy and the length of these questionnaires, which could potentially burden respondents and affect the quality of the data collected. This decision was also rooted in the observation that the measurement of satisfaction is conducted in a notably heterogeneous manner across existing questionnaires, lacking a standard, and only partially covering the scope of satisfaction. This perspective was shared by several hematologists we collaborate with, including Loïc Ysebaert, who notes that to date, no satisfaction questionnaire has become the reference.

While it's possible to publish using any questionnaire, the main goal of our protocol and studies conducted through Platon is to utilize standardized instruments like the QLQ-C30, allowing for the comparison of results. However, satisfaction with treatment serves as an illuminating indicator, rather than a comparative outcome to judge the superiority of patients' quality of life. It is more of an "insight". This view is endorsed by the Aqualis scientific committee, with whom we co-developed the satisfaction questionnaire. Based on patient feedback and scientific committee recommendations, we have created a simplified, non-standardized version to more effectively capture treatment satisfaction, prioritizing the relevance and comfort of our participants in the data collection process.

The aim is to ensure the highest possible completion rate over time, from T0 to T12. The questionnaire we have implemented is inspired by the CTSQ, featuring questions on the patient's overall satisfaction, the impact of their treatment on daily life, the occurrence of adverse effects and their impact (with a disclaimer directing to the adverse effect reporting portal), and the potential use of support care services.

Additionally, the Girerd questionnaire will help monitoring treatment adherence, providing valuable insights into how patients comply with their prescribed regimens.

Sample Size Estimations: - Given the observational nature of the study and the descriptive nature of the primary objective, no pre-defined hypothesis testing is expected to be used to address the primary objective. - Assuming a 20% loss of follow-up, the number of patients to address the exploratory objective will be 120*0.8=96. Statistical Analysis: With a sample size of 120 patients (treated with acalabrutinib as a first-line therapy), we will have enough power to detect a change (including an improvement) in the QoL of patients over time with one QoL (EORTC-QLQ-C30). A comprehensive statistical analysis plan (SAP) will be developed before the first analysis and finalized before the database lock. A descriptive analysis will be conducted on all variables for which data have been extracted for the overall study population and sub-groups of interest. Continuous, quantitative, variable summaries will include: the number of patients (N) (with non-missing values), mean, standard deviation (SD), median, minimum, maximum, 1st, and 3rd quartiles. Categorical, qualitative, variables summaries will include the frequency and percentage of patients per category. The denominator for percentage calculations will be based on the number of observed data, unless otherwise specified. All applicable statistical tests will be two-sided and will be performed at a 5% significance level. Missing values will not be imputed. Results will be presented overall and by treatment line and by age group, as specified in the study objectives. Additional subgroups of interest may be further investigated and discussed in the protocol and/or the SAP.

연구 유형

관찰

등록 (추정된)

120

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Saint-Affrique, 프랑스
        • 모병
        • Research Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

The study population will be a subgroup of patients enrolled in PLATON database as described below.

Inclusion criteria:

The following patients will be eligible for inclusion :

  • Patient enrolled in the PLATON database
  • Patient ≥18 years old
  • Treatment naïve CLL patient treated with acalabrutinib in a real life setting. Treatment pattern is Acala mono or Acala + Obinutuzumab
  • Patient who do not object to his health data collected in PLATON study being re-use for analysis/research purpose
  • Patients who started Acala but discontinued before 12 months are also included.

Exclusion criteria:

  • Pregnant women
  • Patients under protection of justice
  • Patients over the age of 18 and unable to express their non-opposition
  • Patients with prior CLL treatments

설명

Inclusion Criteria:

  • The following patients will be eligible for inclusion in the AQUALIS study :
  • -Patient enrolled in the PLATON database
  • -Patient ≥18 years old
  • -Treatment naïve CLL patient treated with acalabrutinib in a real life setting. Treatment pattern is Acala mono or Acala + Obinutuzumab
  • -Patient who do not object to his health data collected in PLATON study being re-use for analysis/research purpose
  • -Patients who started Acala but discontinued before 12 months are also included.
  • Exclusion criteria:
  • -Pregnant women
  • -Patients under protection of justice
  • -Patients over the age of 18 and unable to express their non-opposition
  • -Patients with prior CLL treatments

Exclusion Criteria:

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: RETROSPECTIVE

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To measure QoL score of CLL patients treated with acalabrutinib, from treatment initiation and up to 12 months
기간: From treatment initiation and up to 12 months
  • Overall scores and scores in each domain of QoL questionnaires (EORTC-QLQ-C30 ) at acalabrutinib treatment initiation and at 3, 6, 9 and 12 months after initiation
  • Proportion of patients with an increase, a decrease, or no change in QoL scores over time (between each time point)
From treatment initiation and up to 12 months

2차 결과 측정

결과 측정
측정값 설명
기간
To describe QoL and precisely the level of all symptoms
기간: Treatment initiation
  • Patients demographics at acalabrutinib treatment initiation
  • Clinical characteristics at acalabrutinib treatment initiation
Treatment initiation
To describe QoL and precisely the level and evolution of all symptoms
기간: From treatment initiation and up to 12 months
  • Clinical characteristics quarterly up to 12 months
  • Score is calculated with standardized EORTC-CLL17 questionnaire At acalabrutinib treatment initiation and at 3, 6, 9 and 12 months after initiation
From treatment initiation and up to 12 months
Data outcomes analyze and link together
기간: From treatment initiation and up to 12 months

The severity of symptoms and the interference with daily living caused by these symptoms will be assessed using EORTC QLQ-CLL17 questionnaire. The overall scores of the QLQ-CLL17 questionnaire will be presented: at acalabrutinib treatment initiation and at 3, 6, 9 and 12 months after initiation.

A mixed model will be used on repeated measurements of total QLQ-CLL17 score to study the evolution of QLQ-CLL17 after acalabrutinib treatment initiation. The model will be adjusted on age and sex and time of measurement as fixed effect.

Disease status will be described quarterly up to 12 months after treatment initiation according to the following status:

-missing value (patients not followed or missing score), complete response, partial response, partial response with lymphocytosis, stable disease, progressive disease Disease status will be analysed according to a sunburst diagram and a Sankey diagram.

From treatment initiation and up to 12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 28일

기본 완료 (추정된)

2026년 12월 31일

연구 완료 (추정된)

2026년 12월 31일

연구 등록 날짜

최초 제출

2024년 7월 17일

QC 기준을 충족하는 최초 제출

2024년 8월 6일

처음 게시됨 (실제)

2024년 8월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 27일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 23일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD 공유 기간

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 공유 액세스 기준

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다